About MediPaCe
Our Mission
Who We Are
Jenny combines strategic thinking with deep behavioural insights to help pharmaceutical leaders move beyond performative engagement and embed meaningful patient partnership into the core of their strategies and program delivery. As CEO of MediPaCe, she brings over 15 years of leadership across AstraZeneca, GlaxoSmithKline, Cancer Research UK, and the NHS. She is a recognized authority in operationalising patient-centred research to improve trial quality, inclusion, and real-world outcomes.
Jenny’s expertise is uniquely grounded in both clinical and behavioural science, holding an MSc in Psychology and Behaviour Change and a PhD from the University of Cambridge in pain perception. This background allows her to apply rigorous scientific methodology to complex organizational challenges, ensuring solutions are evidence-based and regulatory-compliant while remaining nimble and innovative.
What defines Jenny is her warm, collaborative approach and the belief that ‘partnership means partnership’. By meeting partners as equals and blending technical excellence with authenticity, she fosters the trusted relationships necessary to deliver active patient benefits and drive lasting, measurable impact and value across the healthcare ecosystem.
Chi Pakarinen helps pharmaceutical leaders align internal R&D decisions with the right patient data at the right time, driving the delivery of more inclusive treatments and improved health outcomes.
As Head of the PMO at MediPaCe, Chi is a recognized leader who has shaped global standards through her work with DIA Global and her role in establishing Patient Focused Medicines Development (PFMD). A master of high-impact collaborations, she currently co-leads Project-COMFORT with Eli Lilly and brings deep expertise from consulting for Takeda on global science policy and R&D patient engagement.
Chi is distinguished by her whole-person, informed approach, moving beyond theory to deliver practical, values-driven implementation. By ensuring healthcare solutions are co-created in equal partnership with patients, she combines technical excellence with a dedicated commitment to diverse voices.
Natalie leverages over 20 years of co-production expertise to help pharmaceutical leaders translate deep behavioural insights into inclusive, patient-centred solutions that drive impact.
Currently Experience and Involvement Lead at MediPaCe, Natalie builds trusted and sustainable relationships between patient communities and industry partners. Her extensive background includes leading the ‘Connect Voices Network’ at RNIB and establishing national co-production frameworks at Action for Blind People. With a foundation in psychology and counselling training, she provides the ‘involvement intelligence’ required to ensure programs are both technically sound and deeply human.
Natalie is distinguished by her strength in accessibility and inclusion. She ensures every project is co-created with those who have lived expertise, moving beyond simple consultation to genuine partnership. Her warm, and relatable approach ensures that diverse patient voices are heard, valued, and integrated into every stage of development.
Charlotte is a Research Executive at MediPaCe who specializes in transforming complex patient experiences into actionable evidence that helps life sciences teams understand unmet needs, engage diverse communities, and make more patient-centred decisions.
With expertise across qualitative and quantitative research, Charlotte has delivered both global and specialist studies, including the landmark Global Epilepsy Needs Study (GENS), spanning 15 countries and more than 5,000 participants. Combining analytical rigour with a deep appreciation of cultural and lived experience, she is passionate about ensuring diverse patient voices shape the evidence that drives meaningful change.
Guy provides high-level strategic guidance and medical insight, leveraging over two decades of pharma leadership to help make patient involvement an operational reality.
As a Founder and Partner at MediPaCe, Guy serves in a non-executive capacity, guiding the team’s activities and strategic vision. He is currently a visiting Senior Lecturer at King’s College London, and his distinguished career includes holding vice presidency roles at AstraZeneca, where he led global initiatives in Patient Centricity and Medical Evidence, and serving as VP and Global Head of Clinical Development and Medical Affairs at Mallinckrodt.
A trained physician, Guy ensures that patient-centred strategies are grounded in clinical excellence and regulatory rigor. He is distinguished by his ability to help the team maintain a united strategic focus while they are embedded in complex projects, providing the invaluable insight and mentorship that comes from a history of driving global pharma strategy.
Pepa delivers complex, human-first healthcare programs with precision, leveraging her deep expertise in digital patient communities to drive impactful, patient-centric solutions for the pharmaceutical industry.
Currently Senior Programme Manager at MediPaCe, Pepa brings over a decade of leadership from HealthUnlocked, where she managed operations for the global peer support network of 1.5 million users and over 300 charities. A master of high-impact delivery, she has tripled the output of complex initiatives in the regulated healthcare sector and lead the data privacy / infoSec audits during M&A in 2020.
Pepa’s unique approach combines technical excellence with a foundation in sociology and systems thinking. Holding an APM Project Management certification, she seamlessly navigates information governance and digital transformation, ensuring every project is both data-driven and deeply informed by the patient voice to improve health outcomes.
Raktim helps industry partners, research organisations and service providers bridge the gap between clinical research and underserved communities, using social research to ensure healthcare is inclusive, equitable, and evidenced.
Currently Research Executive and Health Equity Lead at MediPaCe, Raktim draws on a background in social anthropology to translate complex social determinants into actionable health insights. During their previous tenure in the charity sector, they managed over 100 stakeholders and led vital involvement work addressing health inequalities and navigating cultural, societal, and commissioning barriers in healthcare for PoC and LGBTIQ+ communities.
A recognized ‘conference organizer extraordinaire’ within the team, Raktim excels at uniting researchers and advocates through large-scale events and co-production workshops. Their expertise in inclusive and innovative research design ensures that diverse patient voices are systematically embedded into pharmaceutical programs, charity strategic deliverables, and policy-change from the start.
Distinguished by a culturally sensitive, human-first approach, Raktim combines technical rigor in biosocial research with a deep commitment to social justice. They provide the cultural competency needed to address health inequalities, ensuring every project is both technically sound and representative of the most vulnerable voices.
Anthony drives innovation by generating robust Patient Experience Data (PED) and evidence (PEE), providing the deep behavioural insights needed to deliver high-standard impactful solutions for partners.
As Senior Research Manager at MediPaCe, Anthony bridges strategy with real-world insights, drawing on his global experience as a clinician, academic and health policy/commissioning reviewer. He is a key contributor to Phase 2 of the Global Epilepsy Needs Study (GENS), a landmark 15-country initiative that established a first-of-its-kind evidence base for the psychosocial challenges of living with epilepsy.
With a PhD in patient education and a background as a healthcare professional, Anthony specializes in using PED and PEE to provide the right evidence for key strategic decisions across the value-chain, commissioning, and patient support programs.
What sets Anthony apart is his personable approach whilst honing down on the specific questions that need addressing. By integrating technically rigorous evidence with the authentic lived experience of patients, he co-creates optimised and evidenced solutions to drive change in global healthcare.
Our Core Values
Compassion
Being relatable, respectful, welcoming, and having a human-centric approach.
Collaboration
Finding unity, learning from difference, open-minded, welcoming, inclusive, and collaborative approach.
Social Responsibility
Commitment to improvement for all.
Excellence
Innovative problem solving. Consistent, high-quality standards on all projects.
Transparency
Transparent ways of working. Being clear, open and honest.
What Makes Us Different






We have diverse experiences both within and outside pharma that increase our ability to address challenges and offer solutions from a wide knowledge base.
We offer both standard and fully outsourced services and have an unparalleled multi-stakeholder program delivery unit to ensure end-to-end continuity, innovation, action and measured impact.